It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17 09:51 ET

TGA Annual Best Action Game Award! "Black Myth: Wukong" sets a new milestone for Chinese gaming.

① On December 13, China's first 3A game "Black Myth: Wukong" won TGA's "Game of the Year" award and the "Players' Voice Award"; ② The game, developed by Game Science, is inspired by "Journey to the West" and has received widespread praise for its graphics, combat system, and storytelling; ③ "Black Myth" was nominated for four awards at TGA and won the 2024 Golden Joystick Award for "Game of the Year" among other awards.

cls.cnDec 13 00:13 ET

Not recognized by the capital markets? Guangxi Liuyao Group: The company's stock price does not match its value | Direct coverage of the earnings conference.

1. At the earnings conference, the chairman of guangxi liuyao group, Zhu Chaoyang, stated that the company's market cap, stock price, and company value are not aligned; 2. The company secretary Xu Yang stated that the company will improve the issue of high accounts receivable through measures such as strengthening the assessment of collection indicators for business personnel; 3. Xu Yang introduced the progress of the company's AI application business in response to investors' concerns.

cls.cnDec 9 07:31 ET

henan lingrui pharmaceutical plans to acquire Silver Valley Pharmaceuticals for 0.782 billion. Traditional Chinese medicine patch and plaster leading the cross-border pharmaceutical market | Quick reading announcement

①Henan Lingrui Pharmaceutical intends to acquire all the equity of Silver Valley Pharmaceutical for 0.782 billion yuan, entering the market of innovative drugs in chemical medicine. ②According to Mononucleosis Medical Data, Silver Valley Pharmaceutical's sales in 2023 exceeded 0.4 billion yuan, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of Class 1 new drug Biti Cong quickly. ③If the acquisition of Silver Valley Pharmaceutical proceeds smoothly, the company's previously set stock-based incentive unlocking target may be difficult to achieve or significantly reduced.

cls.cnDec 4 10:07 ET

beijing tongrentang channel research: the high-end series has started to layout, there are still "gaps" in the out-of-hospital channels, and mergers and acquisitions have taken root in the in-hospital market | company research

① This Friday, the chairman of beijing tongrentang, Di Shubing, officially assumes the role of general manager of beijing tongrentang Group. ② The high-end imperial medicine series is primarily sold in beijing tongrentang pharmacies and remains hard to find in some city chain pharmacies. The company stated that the overall sales situation is in line with expectations. ③ beijing tongrentang Commercial Company acquired 51% of Honghui Medical for 0.105 billion, exploring the medical market, but there are still gaps in the outpatient medium and large chain market.

cls.cnNov 30 09:42 ET

Henan Lingrui Pharmaceutical discloses a stock-based incentive plan Unveiling conditions: average annual double-digit growth in non-GAAP net income | Speed ​​reading announcement

①Henan Lingrui Pharmaceutical has announced a new round of restricted stock incentive plan and employee stock ownership plan, slightly lowering the assessment target compared to the previous incentive plan, but still maintaining a double-digit non-GAAP performance assessment requirement. ②In addition to Henan Lingrui Pharmaceutical, tibet cheezheng tibetan medicine has also previously announced an employee stock ownership plan with higher assessment targets, and the industry expects bone health to be a high-potential category in the out-of-hospital market.

cls.cnNov 29 10:25 ET